Therapeutics Plc Gout Discovery Articles & Analysis: Older
33 news found
CD BioGlyco, a leading provider in the field of glycoproteomics, has recently updated its Glycoprotein Quantification Service. This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational ...
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the different types of quality control (QC) required for iPSCs with a ...
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. HLA typing, the process of identifying ...
Creative Proteomics, a prominent provider of proteomics services, has recently unveiled its highly anticipated Far-Western Blot Analysis service. This service has the potential to transform our understanding of complex protein-protein interactions, opening new avenues for advancements in drug discovery and therapeutic development. Protein-protein interactions serve as the building blocks of ...
BIO Investor Forum Company Snapshot: InvivoSciences What is your company’s lead product or technology? InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D ...
We are excited to announce that Gustav Mahler is hired as the Chief Executive Officer of Ncardia and Cellistic and will join the Board of Directors. Our founder Stefan Braam will assume the role of President and Chief Technical Officer and will remain in the board of directors. With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world ...
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ...
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment ...
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, ...
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from ...
Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency. Totalling £472,000, the grant will facilitate the ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem cell biology and regenerative medicine. The Stem Cell Spaceshot Grant is open to PhD-level scientists and PhD ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry. Orbit will combine its leading peptide discovery platform and experience with WuXi ...
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP ...
HemoShear Therapeutics, Inc. announced today that a second target identified utilizing the company’s REVEAL-Tx™ human disease modeling platform has been selected by Takeda Pharmaceutical Company Limited (“Takeda”) for further drug discovery activities for nonalcoholic steatohepatitis (NASH). This marks the successful completion of HemoShear’s exclusive collaboration ...
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). ...
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer ...
Two recent studies demonstrated that the scientific method that serves as the basis for C2N Diagnostics’ PrecivityAD™ blood test scored best compared to others assays in their respective ability to identify amyloid plaque. The C2N Diagnostics PrecivityAD™ blood test that clinicians use to aid in diagnosing Alzheimer’s disease is underpinned by the liquid ...